Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
| Status: | Archived |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2009 |
A Single-dose, Placebo-controlled, Stratified, Randomized, Double-blind, Crossover to Study Pharmacodynamic Effects of AQW051 Followed by a 4-week Multiple-dose Safety and Tolerability in People With Chronic Stable Schizophrenia.
Part 1 of the study will assess the enhancement of task-related brain activation (BOLD
response) in key brain areas in schizophrenia during the performance of working memory,
episodic memory and visual activation tasks as measured by functional magnetic resonance
imaging (fMRI) in people with schizophrenia. Part 2 of the study will assess the safety and
tolerability of multiple doses of AQW051 in people with schizophrenia.
We found this trial at
7
sites
Washington University Washington University creates an environment to encourage and support an ethos of wide-ranging...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Columbia Presbyterian Med Ctr On January 1, 1998, The New York Hospital publicly announced its...
Click here to add this to my saved trials